Corbus Pharmaceuticals Holdings, Inc.
CRBP
$10.03
$0.141.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 92.77% | 78.84% | 3.38% | -0.05% | -6.54% |
| Gross Profit | -92.77% | -78.84% | -3.38% | 0.05% | 6.54% |
| SG&A Expenses | 18.28% | 20.99% | 18.62% | 3.03% | -14.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 63.97% | 54.41% | 8.08% | 0.98% | -9.58% |
| Operating Income | -63.97% | -54.41% | -8.08% | -0.98% | 9.58% |
| Income Before Tax | -65.72% | -48.97% | 9.85% | 18.46% | 24.29% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -65.72% | -48.97% | 9.85% | 18.46% | 24.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.72% | -48.97% | 9.85% | 18.46% | 24.29% |
| EBIT | -63.97% | -54.41% | -8.08% | -0.98% | 9.58% |
| EBITDA | -65.41% | -55.57% | -8.32% | -1.16% | 9.48% |
| EPS Basic | 18.15% | 39.37% | 64.71% | 57.99% | 47.14% |
| Normalized Basic EPS | 18.16% | 39.37% | 64.71% | 58.15% | 47.34% |
| EPS Diluted | 18.15% | 39.37% | 64.71% | 57.99% | 47.14% |
| Normalized Diluted EPS | 18.16% | 39.37% | 64.71% | 58.15% | 47.34% |
| Average Basic Shares Outstanding | 72.40% | 121.36% | 151.68% | 109.93% | 67.91% |
| Average Diluted Shares Outstanding | 72.40% | 121.36% | 151.68% | 109.93% | 67.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |